Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph F Merola

Showing results (291-300 of 394) with videos related to

Pageof 40
Sort By:
Dermatology and Therapy|July 9, 2024
Correction: Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis SeverityApril W Armstrong, Tarannum Jaleel, Joseph F Merola, et al.
The Journal of Rheumatology|November 1, 2022
Treatment of Psoriasis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment RecommendationsKristina Callis Duffin, Luis Daniel Mazzuoccolo, María Julia Cura, et al.
JAMA Dermatology|April 15, 2026
International Eczema Council Definitions of Low Disease Activity and Remission in Atopic Dermatitis: A Consensus StatementJoseph F Merola, Beth A Childs, Brooke R Bartley, et al.
JAMA Dermatology|August 20, 2025
Comparative Risk of Infection and Prevalence of Combination Targeted Therapy in Psoriatic ArthritisAlexander Wu, Arianna Zhang, Yujia Guo, et al.
Dermatology and Therapy|May 30, 2024
Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis SeverityApril W Armstrong, Tarannum Jaleel, Joseph F Merola, et al.
Nature Reviews. Rheumatology|February 16, 2021
Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus studyLourdes M Perez-Chada, Rebecca H Haberman, Vinod Chandran, et al.
BMJ Open|February 22, 2017
Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomesLinnea Thorlacius, John R Ingram, Amit Garg, et al.
International Journal of Dermatology|December 10, 2020
Measuring fatigue: a meta-reviewMyrela O Machado, Na-Young Cindy Kang, Felicia Tai, et al.
Clinical Rheumatology|June 6, 2024
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 studyChristopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.
JID Innovations : Skin Science From Molecules to Population Health|August 16, 2024
Prevalence and Impact of Unacceptable Symptom State among Patients with Psoriatic Arthritis: Results from the National Psoriasis Foundation's 2019 Annual SurveyMelissa P Zundell, Alexis R Ogdie-Beatty, Lourdes Perez-Chada, et al.
Pageof 40

Showing results (291-300 of 394) with videos related to

Sort By:
Pageof 40
Dermatology and Therapy|July 9, 2024
Correction: Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis SeverityApril W Armstrong, Tarannum Jaleel, Joseph F Merola, et al.
The Journal of Rheumatology|November 1, 2022
Treatment of Psoriasis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment RecommendationsKristina Callis Duffin, Luis Daniel Mazzuoccolo, María Julia Cura, et al.
JAMA Dermatology|April 15, 2026
International Eczema Council Definitions of Low Disease Activity and Remission in Atopic Dermatitis: A Consensus StatementJoseph F Merola, Beth A Childs, Brooke R Bartley, et al.
JAMA Dermatology|August 20, 2025
Comparative Risk of Infection and Prevalence of Combination Targeted Therapy in Psoriatic ArthritisAlexander Wu, Arianna Zhang, Yujia Guo, et al.
Dermatology and Therapy|May 30, 2024
Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis SeverityApril W Armstrong, Tarannum Jaleel, Joseph F Merola, et al.
Nature Reviews. Rheumatology|February 16, 2021
Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus studyLourdes M Perez-Chada, Rebecca H Haberman, Vinod Chandran, et al.
BMJ Open|February 22, 2017
Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomesLinnea Thorlacius, John R Ingram, Amit Garg, et al.
International Journal of Dermatology|December 10, 2020
Measuring fatigue: a meta-reviewMyrela O Machado, Na-Young Cindy Kang, Felicia Tai, et al.
Clinical Rheumatology|June 6, 2024
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 studyChristopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.
JID Innovations : Skin Science From Molecules to Population Health|August 16, 2024
Prevalence and Impact of Unacceptable Symptom State among Patients with Psoriatic Arthritis: Results from the National Psoriasis Foundation's 2019 Annual SurveyMelissa P Zundell, Alexis R Ogdie-Beatty, Lourdes Perez-Chada, et al.
Pageof 40